Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1590MR)

This product GTTS-WQ1590MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Facioscapulohumeral muscular dystrophy (FSHMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1590MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15513MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ4951MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ4841MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ9452MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ2772MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ13950MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ9748MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ7803MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GS-HIV
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW